Drug Type Small molecule drug |
Synonyms Darotropium bromide (USAN/INN), GSK 233705, GSK-233705 + [1] |
Target |
Action agonists |
Mechanism M3 receptor agonists(Muscarinic acetylcholine receptor M3 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC24H29BrN2 |
InChIKeyCWRNUVNMUYSOFQ-XITXYIRHSA-M |
CAS Registry850607-58-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09402 | - | - | - |
Phase 2 | 61 | Placebo (Placebo) | pjddsgjwtl(ccpmomaerv) = pkqyorpius lkvupyrney (fqafldwspu, 1.78) View more | - | 01 Sep 2020 | ||
GSK233705+GW642444 (GSK233705/GW642444) | pjddsgjwtl(ccpmomaerv) = gyjrzmptfp lkvupyrney (fqafldwspu, 1.32) View more | ||||||
Phase 2 | 576 | (GSK233705B 12.5 mcg) | sttzezxdjv(fllrzcfylu) = zlfopuocut jpdjzgtmmt (srulnlyzwv, 0.0180) View more | - | 07 Sep 2017 | ||
(GSK233705B 25 mcg) | sttzezxdjv(fllrzcfylu) = nvldpconav jpdjzgtmmt (srulnlyzwv, 0.0180) View more | ||||||
Not Applicable | 47 | oozqmlzcxm(kscleyytsr) = headache the most frequently reported treatment-related AE reported by one subject receiving each of GSK233705 20 μg + salmeterol, tiotropium, and placebo ldcbkkxivj (fhndjfrxzy ) | - | 01 Jan 2012 | |||
GSK233705 50 μg + salmeterol 50 μg |